https://doi.org/10.4081/hmr.v2i3.374

The effects of combined treatment using paclitaxel and zoledronic acid on tumour cells and endothelial cells in vitro

Vol. 2 No. 3: Cervo Preclinical Working Conference, Cervo Ligure, October 6-8, 2005
Published: June 8, 2009
Abstract Views: 218
PDF: 430
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.

Authors

M Michailidou
support@pagepress.org
HL Neville-Webbe
JK Woodward
DV Lefley
There is increasing use of combined therapies in oncology, but the optimal drug combinations and sequences have in many cases not been determined. The use of bisphosphonates (BPs) together with cytotoxic drugs may be a favourable combination, as BPs like Zometa are usually well tolerated causing few side effects in the patients.1 In this study we have investigating the effects of zoledronic acid (Zometa) in combination with the commonly used cytotoxic drug paclitaxel, in order to determine whether this combination does induce increased levels of apoptotic cell death in breast cancer cells in vitro.2

Dimensions

Altmetric

PlumX Metrics

Downloads

Citations

Crossref
Scopus
Google Scholar
Europe PMC

Supporting Agencies

How to Cite

Michailidou, M., Neville-Webbe, H., Woodward, J., & Lefley, D. (2009). The effects of combined treatment using paclitaxel and zoledronic acid on tumour cells and endothelial cells in vitro. Hematology Meeting Reports (formerly Haematologica Reports), 2(3). https://doi.org/10.4081/hmr.v2i3.374
Authors who publish with this journal agree to the following terms: Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution License that allows others to share the work with an acknowledgement of the work's authorship and initial publication in this journal. Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgement of its initial publication in this journal. Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (See The Effect of Open Access).